Pharvaris N.V. (PHVS)

21.25 -0.04 (-0.19%) At close: 04:00PM EDT

Pharvaris N.V.

Emmy Noetherweg 2
Leiden 2333 BK
Netherlands
31 71 203 6410
https://pharvaris.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 82

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Berndt Axel Edvard Modig CPA, M.B.A.	Co-Founder, CEO & Executive Director	569.39k	N/A	1959
Ms. Anna Nijdam M.Sc., R.A.	Head of Strategic Finance & Principal Accounting Officer	N/A	N/A	1981
Dr. Stefan Abele Ph.D.	Chief Technology Operations Officer	N/A	N/A	1970
Ms. Joan Schmidt J.D.	Chief Legal Officer	N/A	N/A	1964
Ms. Annick Deschoolmeester	Chief Human Resources Officer	N/A	N/A	1973
Dr. Peng Lu M.D., Ph.D.	Chief Medical Officer	N/A	N/A	1978
Dr. Anne A. Lesage Ph.D.	Chief Early Development Officer	N/A	N/A	1961
Dr. Morgan Conn Ph.D.	Chief Business Officer	N/A	N/A	1969
Mr. Wim Souverijns Ph.D.	Chief Commercial Officer	N/A	N/A	1971
Mr. David W. Nassif J.D.	Chief Financial Officer	N/A	N/A	1954

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Corporate governance

Pharvaris N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.